PL3194567T3 - Probiotyczne szczepy bifidobacterium adolescentis - Google Patents
Probiotyczne szczepy bifidobacterium adolescentisInfo
- Publication number
- PL3194567T3 PL3194567T3 PL15763232T PL15763232T PL3194567T3 PL 3194567 T3 PL3194567 T3 PL 3194567T3 PL 15763232 T PL15763232 T PL 15763232T PL 15763232 T PL15763232 T PL 15763232T PL 3194567 T3 PL3194567 T3 PL 3194567T3
- Authority
- PL
- Poland
- Prior art keywords
- bifidobacterium adolescentis
- probiotic bifidobacterium
- strains
- adolescentis strains
- probiotic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182859 | 2014-08-29 | ||
| PCT/EP2015/069740 WO2016030504A1 (en) | 2014-08-29 | 2015-08-28 | Probiotic bifidobacterium adolescentis strains |
| EP15763232.4A EP3194567B1 (en) | 2014-08-29 | 2015-08-28 | Probiotic bifidobacterium adolescentis strains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3194567T3 true PL3194567T3 (pl) | 2020-06-15 |
Family
ID=51421974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15763232T PL3194567T3 (pl) | 2014-08-29 | 2015-08-28 | Probiotyczne szczepy bifidobacterium adolescentis |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10022408B2 (pl) |
| EP (1) | EP3194567B1 (pl) |
| CN (2) | CN112195128B (pl) |
| DK (1) | DK3194567T3 (pl) |
| ES (1) | ES2768690T3 (pl) |
| PL (1) | PL3194567T3 (pl) |
| WO (1) | WO2016030504A1 (pl) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10881674B2 (en) * | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP3172973B1 (en) * | 2015-11-27 | 2020-04-08 | DAFLORN Ltd. | Probiotic formula, process of its preparation and use |
| IT201600084470A1 (it) * | 2016-08-10 | 2018-02-10 | Probiotical Spa | Composizione per uso nel trattamento del disturbo depressivo maggiore |
| DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| KR102205829B1 (ko) * | 2017-06-14 | 2021-01-21 | 기초과학연구원 | 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체 |
| EP3715448A4 (en) * | 2017-09-29 | 2021-06-30 | University - Industry Cooperation Group of Kyung Hee University | NOVEL LACTIC ACID BACTERIA AND USES THEREOF |
| US12139767B2 (en) * | 2018-05-22 | 2024-11-12 | University Of Maryland, Baltimore | Composition and methods for predicting necrotizing enterocolitis in preterm infants |
| WO2019232513A1 (en) * | 2018-06-01 | 2019-12-05 | Evolve Biosystems, Inc. | Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires |
| CN110721203A (zh) * | 2018-07-17 | 2020-01-24 | 深圳爱米基因科技有限责任公司 | 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用 |
| WO2020037533A1 (zh) * | 2018-08-22 | 2020-02-27 | 江南大学 | 长双歧杆菌婴儿亚种ccfm687、其发酵食品及其应用 |
| US20220290095A1 (en) * | 2018-08-22 | 2022-09-15 | Jiangnan University | Bifidobacterium breve CCFM1025, Food Fermented Thereby and Application Thereof |
| CN109517759A (zh) * | 2018-12-04 | 2019-03-26 | 山西大学 | 一种适于肠道定植、提高消化率和免疫力的枯草芽孢杆菌制剂及其制备方法 |
| CN109628358B (zh) * | 2019-02-20 | 2021-03-19 | 无限极(中国)有限公司 | 一种复合益生菌及其应用 |
| CN109666615B (zh) * | 2019-02-20 | 2021-03-19 | 无限极(中国)有限公司 | 一种益生菌组合物及其应用 |
| IT201900011193A1 (it) * | 2019-07-08 | 2021-01-08 | Sofar Spa | Ceppo di batteri Bifidobacterium bifidum, sue composizioni e relativi usi |
| JP7013419B2 (ja) * | 2019-08-07 | 2022-02-15 | 日清食品ホールディングス株式会社 | 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌 |
| CN110331118B (zh) * | 2019-08-19 | 2020-12-15 | 江南大学 | 青春双歧杆菌ccfm1061、其发酵食品及菌剂制备方法 |
| CN110432332B (zh) * | 2019-08-20 | 2021-10-26 | 江南大学 | 青春双歧杆菌ccfm1062、其发酵食品及菌剂制备方法 |
| CN110368406B (zh) * | 2019-08-20 | 2021-02-12 | 江南大学 | 青春双歧杆菌ccfm1062在制备功能性菌剂、食品和/或药物中的应用 |
| CN110616167B (zh) * | 2019-08-22 | 2022-02-01 | 江南大学 | 能够缓解特应性皮炎的双歧杆菌及其应用 |
| CN110893194B (zh) * | 2019-11-20 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用 |
| CN111154694A (zh) * | 2020-02-09 | 2020-05-15 | 西南交通大学 | 一种微生物发酵菌剂及其制备方法和应用 |
| WO2021172900A1 (ko) * | 2020-02-26 | 2021-09-02 | 주식회사 지아이바이옴 | 락토바실러스 헬베티쿠스 균주 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
| BR112022017240A2 (pt) * | 2020-03-09 | 2022-10-18 | Sofar Spa | Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório |
| IT202000006448A1 (it) | 2020-03-26 | 2021-09-26 | Sofar Spa | Ceppi di batteri, loro composizioni e loro uso in un metodo per il trattamento di una carenza di vitamina d,e di disturbi associati |
| CN112111424B (zh) * | 2020-09-03 | 2022-07-22 | 江南大学 | 一株可缓解类风湿性关节炎的短双歧杆菌及其应用 |
| CN112956696A (zh) * | 2021-02-10 | 2021-06-15 | 北京华元生物技术研究院 | 乳双歧杆菌在防治精神障碍中的用途 |
| CA3208064A1 (en) | 2021-02-10 | 2022-08-18 | Zhongke Wisbiom(Beijing)Biotechnology Co., Ltd. | Bifidobacterium animalis subsp. lactis and use thereof |
| CN113249264B (zh) * | 2021-06-03 | 2021-11-23 | 北京量化健康科技有限公司 | 一株青春双歧杆菌及其在代谢综合征中的应用 |
| CN113604493B (zh) * | 2021-06-13 | 2023-08-01 | 兰州大学 | Ldh、表达ldh的重组质粒、表达ldh的重组益生菌及应用 |
| CN113684201A (zh) * | 2021-08-27 | 2021-11-23 | 日照市畜牧兽医管理服务中心 | 基于Caco-2细胞高效诱变筛选肠道定植益生菌的育种方法 |
| CN115721664A (zh) * | 2021-08-31 | 2023-03-03 | 瑞微(深圳)生物科技有限公司 | 青春双歧杆菌在制备用于治疗炎症相关疾病的药物中的应用 |
| CN119317439A (zh) * | 2022-06-28 | 2025-01-14 | 科·汉森有限公司 | 用于影响低度炎症的用途的双歧杆菌 |
| CN116672369A (zh) * | 2022-10-10 | 2023-09-01 | 浙江大学 | 青春双歧杆菌在预防和/或治疗结直肠癌产品制备中的应用 |
| WO2024107835A2 (en) * | 2022-11-15 | 2024-05-23 | Newgen 27, Llc D/B/A Doctor's Biome | Probiotic formulations and methods of use thereof |
| CN117286049B (zh) * | 2023-07-13 | 2024-09-20 | 西南大学 | 一株能改善酒精性肝损伤的副干酪乳杆菌lp.dcrff018及其应用 |
| CN116875516B (zh) * | 2023-09-06 | 2023-12-08 | 上海上药信谊药厂有限公司 | 青春双歧杆菌ba-3及其在抗衰老、抗氧化和抗炎中的应用 |
| CN117070425B (zh) * | 2023-10-10 | 2024-03-08 | 广东益可维生物技术有限公司 | 提高益生菌在机体内代谢稳定性的工艺方法及益生菌冻干粉 |
| CN118662535B (zh) * | 2024-05-17 | 2025-04-04 | 广东药科大学 | 青春双歧杆菌及其代谢物在制备改善肝损伤药物中的应用 |
| CN119464112A (zh) * | 2024-09-30 | 2025-02-18 | 深圳未知君生物科技有限公司 | 一株能够缓解便秘的青春双歧杆菌及其应用 |
| CN119162041A (zh) * | 2024-09-30 | 2024-12-20 | 内蒙古农业大学 | 青春双歧杆菌b-201及其活性物质的后生元制备和应用 |
| CN120041335A (zh) * | 2025-02-21 | 2025-05-27 | 江南大学 | 一株具有调节昼夜节律显著改善认知记忆能力的长双歧杆菌及其应用 |
| CN120624307A (zh) * | 2025-08-13 | 2025-09-12 | 浙江大学 | 一种预防和/或治疗溃疡性结肠炎的菌株、混合益生菌及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20002445A0 (fi) * | 2000-11-08 | 2000-11-08 | Raisio Yhtymae Oyj | Menetelmä bakteerien seulomiseksi |
| WO2006013588A1 (en) * | 2004-08-05 | 2006-02-09 | Anidral S.R.L. | Folic acid producing bifidobacterium bacterial strains, formulations and use thereof |
| ITMI20080898A1 (it) * | 2008-05-16 | 2009-11-17 | Probiotical Spa | Uso di batteri probiotici per il trattamento della iperomocisteinemia |
| EP2498789B1 (en) * | 2009-11-11 | 2016-06-22 | Alimentary Health Limited | Probiotic bifidobacterium strain |
| KR101335670B1 (ko) | 2011-12-16 | 2013-12-03 | 삼육대학교산학협력단 | B형 간염 바이러스에 대한 항바이러스 활성을 나타내는 비피도박테리움 아돌레센티스 spm0212, 및 이를 포함하는 b형 간염 예방 및 치료용 약학적 조성물 |
-
2015
- 2015-08-28 ES ES15763232T patent/ES2768690T3/es active Active
- 2015-08-28 CN CN202011124149.2A patent/CN112195128B/zh active Active
- 2015-08-28 US US15/504,913 patent/US10022408B2/en active Active
- 2015-08-28 CN CN201580045802.7A patent/CN107109348B/zh active Active
- 2015-08-28 PL PL15763232T patent/PL3194567T3/pl unknown
- 2015-08-28 WO PCT/EP2015/069740 patent/WO2016030504A1/en not_active Ceased
- 2015-08-28 DK DK15763232.4T patent/DK3194567T3/da active
- 2015-08-28 EP EP15763232.4A patent/EP3194567B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170252382A1 (en) | 2017-09-07 |
| WO2016030504A1 (en) | 2016-03-03 |
| CN107109348B (zh) | 2020-11-10 |
| CN112195128B (zh) | 2023-05-02 |
| ES2768690T3 (es) | 2020-06-23 |
| EP3194567A1 (en) | 2017-07-26 |
| US10022408B2 (en) | 2018-07-17 |
| EP3194567B1 (en) | 2019-10-30 |
| BR112017002934A2 (pt) | 2018-01-30 |
| DK3194567T3 (da) | 2020-01-13 |
| CN112195128A (zh) | 2021-01-08 |
| CN107109348A (zh) | 2017-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3194567T3 (pl) | Probiotyczne szczepy bifidobacterium adolescentis | |
| GB201616058D0 (en) | Probiotic composition | |
| ZA201705812B (en) | Recombinant probiotic bacteria | |
| EP3092008A4 (en) | Skin probiotic | |
| PL3116350T3 (pl) | Poduszka podróżna | |
| ZA201803451B (en) | Probiotic compositions and uses thereof | |
| PL3223837T3 (pl) | Lactobacillus do zastosowania jako probiotyk | |
| SG11201607557WA (en) | Novel lactobacillus paracasei strain | |
| GB201409541D0 (en) | Probiotic Bacteria | |
| PL3209307T3 (pl) | Kompozycje probiotyczne i prebiotyczne | |
| IL237033A0 (en) | Sleeve zipper | |
| EP3217992A4 (en) | Probiotic therapeutic applications | |
| IL247869A0 (en) | Formulations of factor ix that have been lyophilized | |
| GB201501938D0 (en) | Probiotic preparation | |
| GB201409468D0 (en) | Bacterium | |
| PL3210612T3 (pl) | Preparat synbiotyczny | |
| IL247535A0 (en) | Fox-viral oncolytic vectors | |
| ZA201606681B (en) | Production of yogurt | |
| ZA202002675B (en) | Probiotic composition | |
| TWI559924B (en) | Novel lactobacillus paracasei subsp. paracasei k66 | |
| PL3237600T3 (pl) | Termostabilne szczepy, ich produkty i sposoby stosowania | |
| TWM490221U (en) | Lactobacillus cake | |
| LT3261452T (lt) | Nauja termoatspari lactobacillus | |
| HK1234431A1 (en) | Probiotic bifidobacterium adolescentis strains | |
| GB201616056D0 (en) | Probiotic composition |